HomeCompareBMY vs HESM

BMY vs HESM: Dividend Comparison 2026

BMY yields 4.17% · HESM yields 7.51%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HESM wins by $23.67M in total portfolio value
10 years
BMY
BMY
● Live price
4.17%
Share price
$59.73
Annual div
$2.49
5Y div CAGR
37%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$120.5K
Annual income
$39,823.66
Full BMY calculator →
HESM
HESM
● Live price
7.51%
Share price
$39.50
Annual div
$2.97
5Y div CAGR
62%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.79M
Annual income
$19,655,759.86
Full HESM calculator →

Portfolio growth — BMY vs HESM

📍 HESM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMYHESM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMY + HESM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMY pays
HESM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMY
Annual income on $10K today (after 15% tax)
$354.34/yr
After 10yr DRIP, annual income (after tax)
$33,850.11/yr
HESM
Annual income on $10K today (after 15% tax)
$638.19/yr
After 10yr DRIP, annual income (after tax)
$16,707,395.88/yr
At 15% tax rate, HESM beats the other by $16,673,545.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMY + HESM for your $10,000?

BMY: 50%HESM: 50%
100% HESM50/50100% BMY
Portfolio after 10yr
$11.96M
Annual income
$9,847,791.76/yr
Blended yield
82.36%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BMY right now

BMY
Analyst Ratings
19
Buy
20
Hold
2
Sell
Consensus: Hold
Price Target
$62.73
+5.0% upside vs current
Range: $40.00 — $75.00
Altman Z
2.3
Piotroski
8/9
HESM
Analyst Ratings
2
Buy
7
Hold
Consensus: Hold
Price Target
$35.00
-11.4% upside vs current
Range: $35.00 — $35.00
Altman Z
2.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMY buys
0
HESM buys
0
No recent congressional trades found for BMY or HESM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMYHESM
Forward yield4.17%7.51%
Annual dividend / share$2.49$2.97
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR37%62%
Portfolio after 10y$120.5K$23.79M
Annual income after 10y$39,823.66$19,655,759.86
Total dividends collected$91.0K$23.42M
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldHold
Analyst price target$62.73$35.00

Year-by-year: BMY vs HESM ($10,000, DRIP)

YearBMY PortfolioBMY Income/yrHESM PortfolioHESM Income/yrGap
1← crossover$11,271$571.12$11,916$1,216.31$645.00HESM
2$12,884$824.20$14,945$2,194.41$2.1KHESM
3$14,993$1,206.32$20,158$4,166.77$5.2KHESM
4$17,839$1,797.27$30,078$8,509.06$12.2KHESM
5$21,826$2,738.11$51,406$19,222.83$29.6KHESM
6$27,643$4,289.31$104,746$49,741.23$77.1KHESM
7$36,534$6,955.64$265,529$153,450.84$229.0KHESM
8$50,861$11,770.13$873,062$588,946.10$822.2KHESM
9$75,402$20,980.23$3,866,015$2,931,838.98$3.79MHESM
10$120,504$39,823.66$23,792,396$19,655,759.86$23.67MHESM

BMY vs HESM: Complete Analysis 2026

BMYHealthcare

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Full BMY Calculator →

HESMStock

Hess Midstream LP owns, develops, operates, and acquires midstream assets. The company operates through three segments: Gathering; Processing and Storage; and Terminaling and Export. The Gathering segment owns natural gas gathering and compression; crude oil gathering systems; and produced water gathering and disposal facilities. Its gathering systems consists of approximately 1,350 miles of high and low pressure natural gas and natural gas liquids gathering pipelines with capacity of approximately 450 million cubic feet per day; and crude oil gathering system comprises approximately 550 miles of crude oil gathering pipelines. The Processing and Storage segment comprises Tioga Gas Plant, a natural gas processing and fractionation plant located in Tioga, North Dakota; a 50% interest in the Little Missouri 4 gas processing plant located in south of the Missouri River in McKenzie County, North Dakota; and Mentor Storage Terminal, a propane storage cavern and rail, and truck loading and unloading facility located in Mentor, Minnesota. The Terminaling and Export segment owns Ramberg terminal facility; Tioga rail terminal; and crude oil rail cars, as well as Johnson's Corner Header System, a crude oil pipeline header system. Hess Midstream LP was founded in 2014 and is based in Houston, Texas.

Full HESM Calculator →
📬

Get this BMY vs HESM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMY vs SCHDBMY vs JEPIBMY vs OBMY vs KOBMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.